Contents
1 Letter to Shareholders
5 LUNESTA®
8 XOPENEX®
12 BROVANA™
14 Additional Opportunities
19 2006 Form 10-K
145 Comparative Stock Performance Chart
146 Corporate Information
IBC Executive Management and Directors

 

   
Sepracor is dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products directed toward serving unmet medical needs. Sepracor’s drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders.
   
     

Cautionary Statement Regarding Forward-Looking Statements

This annual report to stockholders contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial condition, including statements with respect to the safety, efficacy and potential benefits of our products and product candidates, expectations concerning the timing and success of regulatory filings, the development and commercialization of our products and product candidates and possible acquisitions, the scope of patent protection for our products and product candidates and other plans and strategies. All statements other than historical facts included in this report are forward-looking statements.When used in this report the words “expect”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “will”, “estimate”, “goal” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed under “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this report.The forward-looking statements contained in this annual report represent our expectations as of the date of this report and should not be relied upon as representing our expectations as of any other date. Although subsequent events and developments will cause our expectations to change, we specifically disclaim any obligation to provide updates.

All market data and share calculations contained in this report are sourced and derived from IMS Health Incorporated information.